MedBridge Partners with Redox to Expand Its Network of EMR Integrations

HIT Consultant | March 03, 2020

MedBridge, the industry-leading continuing education and patient engagement solution that enables healthcare organizations to improve outcomes and optimize care delivery announced today its partnership with Redox, a healthcare integration platform that allows software vendors to seamlessly integrate with healthcare organizations to securely exchange healthcare data. As part of the partnership, MedBridge will expand its current network of integrations to include leading EMRs, enabling healthcare professionals to quickly collect and record accurate patient information, saving time, and standardizing care coordination.

Spotlight

If your eating and exercise are on point, but you still don’t feel or look the way you want, poor sleep may be to blame. Here’s how to tap into the power of sleep and make rest a daily priority. Everything from lucid thinking, too good decision making, to proper digestion, to high performance, is heavily dependent on getting good quality sleep.


Other News
DIGITAL HEALTHCARE

DECISIO Reveals New Leadership and Closes Series B Funding Round

DECISIO | March 28, 2022

DECISIO has appointed Major General Elder Granger, M.D. to the company's Board of Directors. Dr. Granger is currently President and CEO of The 5Ps, LLC, a healthcare, education, and leadership consulting organization. Prior to his retirement from the US Army, Dr. Granger served as the Deputy Director of TRICARE Management Activity, a Department of Defense (DoD) field activity responsible for operating the Military Health System as a fully integrated healthcare system within DoD. He was responsible for supervising and administering TRICARE programs, providing oversight of high-quality, accessible health care for 9.2 million beneficiaries worldwide. "Dr. Granger joining our board provides enormous value and validation for our company moving forward. His expertise and leadership in the healthcare industry is a welcome addition to our esteemed group of Board of Directors''. Dr. John Holcomb, Co-CEO and Cofounder of DECISIO In addition to his accomplished military career, Dr. Granger is board certified by the American Board of Internal Medicine and the Board of Hematology and Oncology. He is a certified physician executive by the Certifying Commission in Medical Management, the American College of Healthcare Executives, and certified in Medical Quality by the American Board of Medical Quality. Dr. Granger also serves on the Board of Directors for Cerner Corporation, Cigna Corporation and DLH Holdings Corporation and is a member of the Board of Trustees at Rosalind Franklin University. DECISIO is also announcing the official closure of its $18.5 million Series B funding round in February 2022, bringing the total funds raised to date at $31.5 million. The funds from this round will be used for commercialization, continued product development, and operations growth. About DECISIO® DECISIO is a Houston-based digital health company with a customizable clinical decision support platform designed to aggregate and prioritize real-time data, from any device, and present it visually in one place. The flagship product, InsightIQ, uses continuous smart bedside monitoring which enables clinical teams to efficiently identify patients at risk and comply with established clinical guidelines. InsightIQ improves patient outcomes and throughput, optimizes workflow, increases collaboration, thus reducing length of stay and "click" fatigue. Our solutions, including actionable analytics, that can be scaled across an entire health system or used in a single care area. For more information, visit www.decisiohealth.com.

Read More

HEALTH TECHNOLOGY

Future Health announced today that it has completely digitalised its annual in-person event at ExCeL London

Future Health | March 02, 2021

Future Health has completely rebranded during lockdown, and the flagship face-to-face event Future Health Innovations at ExCeL is now complemented by a global virtual conference series, under the brand UK Health Week. Free for delegates to attend, it is CPD and CME accredited. Participants will be able to connect, meet buyers and partake in cross border purchasing, education and deal making, enabling an increased ROI and profitable encounters with its AI powered networking software. Further Health Weeks are being rolled out around the world over the course of the coming months, and will be territory specific. Dawn Barclay-Ross, Event Director commented: “I think there will always be a place for face-to-face events; and we are contracted with ExCeL for a live ‘in person’ event four years in advance to 2025. However, as a result of international travel restrictions, health professionals in global markets are looking for on-line engagement”. Future Health offers buyers and sellers the ability to operate on line, and to research and access the products and services that their hospitals and citizens desperately need. Dawn concluded, “In the immediate post COVID era, health buyers want to be able to operate from the comfort of their desk or smart device, and they now can, from literally anywhere in the world”. AboutFuture Health Future Health is an independent exhibition and conference organiser, based in London in the UK. For further information regarding exhibiting, visiting and sponsorship opportunities at Future Health Innovations or UK Health Week Please call +44 (0) 208 012 8511 Email: hello@futurehealthinnovations.com or to sign up to the Future Health platform, register at www.futurehealthinnovations.com

Read More

FUTURE OF HEALTHCARE

OmniLife Partners With Redox to Add Patient Referral Management Tool to Its End-to-End Communication Platform for Transplant Hospitals.

OmniLife | March 25, 2022

OmniLife, a health technology communication and collaboration platform, has partnered with Redox, the industry-leading electronic health record integration and healthcare interoperability platform, to create a new integrated patient management tool as part of its overarching platform that provides end-to-end communication solutions for transplant hospitals. The new patient modules, OmniReferral and PatientStatus, will allow transplant centers to easily review new referrals and share updates on patient status to providers and allows transplant centers to customize their own digital forms to make it easier for providers to refer and then monitor the activity and status of transplant patients. The tool also integrates into the EHR patient checklists and allows centers using EHRs to easily share patient status updates with referring providers. OmniReferral and PatientStatus is built to be organ agnostic, allowing centers to use the tool across all organ departments and with any referring provider. OmniLife has been leading efforts to improve communication, decision making, and secure information exchange between all stakeholders in the greater allotransplant ecosystem. Additionally, OmniLife is currently participating in a clinical trial funded by the National Institutes of Health (NIH) for a Small Business Innovation Research (SBIR) which includes notable centers such as UPMC Children’s Hospital of Pittsburgh, Loma Linda University Transplant Institute, and Stanford Health Care Transplant Program. About OmniLife OmniLife is a certified Benefit Corporation focused on maximizing the gift of life for purposes of transplantation and research. OmniLife is the only end-to-end communication and clinical workflow software platform that is built specifically to create a more connected and collaborative allotransplant ecosystem.

Read More

FUTURE OF HEALTHCARE

Medicago Announces Publication of Phase 3 COVID-19 Vaccine Study Results in New England Journal of Medicine

Medicago | May 06, 2022

Medicago announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine recombinant, adjuvanted, in the New England Journal of Medicine. The Phase 3 trial studied the two-dose regimen of COVIFENZ® given 21 days apart versus placebo in over 24,000 subjects aged 18 and above. Common side effects in the vaccine group included injection site pain, headache, fatigue, fever, muscle aches, and chills. COVIFENZ® is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 in individuals 18 to 64 years of age. The safety and efficacy of COVIFENZ® in individuals younger than 18 years of age or 65 years and older have not been established. COVIFENZ® has not yet received approval in other jurisdictions. “We are proud to have our Phase 3 clinical trial published in the esteemed New England Journal of Medicine to be shared with the larger scientific community. Medicago’s scientific team has dedicated decades to the development of our proprietary plant-based vaccine manufacturing platform, and we are thrilled to see our results disseminated in this way. We hope that this exchange of research and knowledge will encourage and inspire future innovation in biomedical science and clinical practice.” Marc-André D’Aoust, Executive Vice President, Innovation, Development and Medical Affairs at Medicago COVIFENZ® was authorized for use by Health Canada on February 24, 2022. This is the first authorized COVID-19 vaccine developed by a Canadian-headquartered company, and the first that uses a plant-based protein technology. “The world needs a diverse range of vaccine options to continue to fight COVID-19, and we are proud to be able to contribute,” said Toshifumi Tada, CEO and President at Medicago. About Medicago Medicago is on a mission to help improve global public health using the power of plants. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare, Medicago is a pioneer in plant-based therapeutics. We are proudly rooted in Quebec, with manufacturing capacity in both Canada and the US. Our passionate and curious team of over 500 scientific experts and employees are dedicated to using our technology to provide rapid responses to emerging global health challenges, and to advancing therapeutics against life-threatening diseases worldwide. Medicago is an affiliated company of Mitsubishi Tanabe Pharma Corporation. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation, the majority parent company of Medicago, is one of the large Japanese pharmaceutical companies, with its headquarters in Osaka, Japan. It positions vaccines as one of its key R&D areas and is also working to develop new modalities of vaccines. MTPC will further contribute to the prevention of infectious diseases which is one of the world’s important social issues, by delivering a new option of plant-based VLP vaccine as a new type of vaccine. MTPC is a member of Mitsubishi Chemical Holdings Group.

Read More

Spotlight

If your eating and exercise are on point, but you still don’t feel or look the way you want, poor sleep may be to blame. Here’s how to tap into the power of sleep and make rest a daily priority. Everything from lucid thinking, too good decision making, to proper digestion, to high performance, is heavily dependent on getting good quality sleep.

Resources